Vanguard Fiduciary Trust
HCWB icon

Vanguard Fiduciary Trust’s HCW Biologics HCWB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.5K Buy
6,510
+6,193
+1,954% +$35.1K ﹤0.01% 3939
2026
Q1 		$685 Buy
+317
New +$1.64K ﹤0.01% 4054

Other funds holding HCWB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Vanguard Fiduciary Trust's HCWB Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its HCW Biologics (HCWB) stake by 1,954% in Q2 2026, buying an estimated $35.1K and bringing the position to 6,510 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3939.

Vanguard Fiduciary Trust first reported a position in HCWB in Q1 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • Vanguard Fiduciary Trust held 6,510 shares of HCW Biologics worth $32.5K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 6,193 HCW Biologics shares in Q2 2026, an estimated $35.1K.
  • HCW Biologics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3939 holding.
  • Vanguard Fiduciary Trust first reported a position in HCW Biologics in Q1 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.